Galectin-1 as an Emerging Mediator of Cardiovascular Inflammation: Mechanisms and Therapeutic Opportunities
Galectin-1 (Gal-1), an evolutionarily conserved β-galactoside-binding lectin, controls immune cell homeostasis and tempers acute and chronic inflammation by blunting proinflammatory cytokine synthesis, engaging T-cell apoptotic programs, promoting expansion of T regulatory (Treg) cells, and deactiva...
Guardado en:
| Publicado: |
2018
|
|---|---|
| Materias: | |
| Acceso en línea: | https://bibliotecadigital.exactas.uba.ar/collection/paper/document/paper_09629351_v2018_n_p_Seropian http://hdl.handle.net/20.500.12110/paper_09629351_v2018_n_p_Seropian |
| Aporte de: |
| id |
paper:paper_09629351_v2018_n_p_Seropian |
|---|---|
| record_format |
dspace |
| spelling |
paper:paper_09629351_v2018_n_p_Seropian2023-06-08T15:58:09Z Galectin-1 as an Emerging Mediator of Cardiovascular Inflammation: Mechanisms and Therapeutic Opportunities ecalectin galectin galectin 1 galectin 12 glycan unclassified drug vasculotropin receptor galectin 1 vasculotropin A acute heart infarction antiinflammatory activity atherosclerosis brain ischemia cell differentiation cell expansion cell survival Chagas cardiomyopathy cytokine production heart failure immunocompetent cell mediator pulmonary hypertension regulatory T lymphocyte Review animal homeostasis human inflammation metabolism physiology Animals Galectin 1 Homeostasis Humans Inflammation T-Lymphocytes, Regulatory Vascular Endothelial Growth Factor A Galectin-1 (Gal-1), an evolutionarily conserved β-galactoside-binding lectin, controls immune cell homeostasis and tempers acute and chronic inflammation by blunting proinflammatory cytokine synthesis, engaging T-cell apoptotic programs, promoting expansion of T regulatory (Treg) cells, and deactivating antigen-presenting cells. In addition, this lectin promotes angiogenesis by co-opting the vascular endothelial growth factor receptor (VEGFR) 2 signaling pathway. Since a coordinated network of immunomodulatory and proangiogenic mediators controls cardiac homeostasis, this lectin has been proposed to play a key hierarchical role in cardiac pathophysiology via glycan-dependent regulation of inflammatory responses. Here, we discuss the emerging roles of Gal-1 in cardiovascular diseases including acute myocardial infarction, heart failure, Chagas cardiomyopathy, pulmonary hypertension, and ischemic stroke, highlighting underlying anti-inflammatory mechanisms and therapeutic opportunities. Whereas Gal-1 administration emerges as a potential novel treatment option in acute myocardial infarction and ischemic stroke, Gal-1 blockade may contribute to attenuate pulmonary arterial hypertension. © 2018 Ignacio M. Seropian et al. 2018 https://bibliotecadigital.exactas.uba.ar/collection/paper/document/paper_09629351_v2018_n_p_Seropian http://hdl.handle.net/20.500.12110/paper_09629351_v2018_n_p_Seropian |
| institution |
Universidad de Buenos Aires |
| institution_str |
I-28 |
| repository_str |
R-134 |
| collection |
Biblioteca Digital - Facultad de Ciencias Exactas y Naturales (UBA) |
| topic |
ecalectin galectin galectin 1 galectin 12 glycan unclassified drug vasculotropin receptor galectin 1 vasculotropin A acute heart infarction antiinflammatory activity atherosclerosis brain ischemia cell differentiation cell expansion cell survival Chagas cardiomyopathy cytokine production heart failure immunocompetent cell mediator pulmonary hypertension regulatory T lymphocyte Review animal homeostasis human inflammation metabolism physiology Animals Galectin 1 Homeostasis Humans Inflammation T-Lymphocytes, Regulatory Vascular Endothelial Growth Factor A |
| spellingShingle |
ecalectin galectin galectin 1 galectin 12 glycan unclassified drug vasculotropin receptor galectin 1 vasculotropin A acute heart infarction antiinflammatory activity atherosclerosis brain ischemia cell differentiation cell expansion cell survival Chagas cardiomyopathy cytokine production heart failure immunocompetent cell mediator pulmonary hypertension regulatory T lymphocyte Review animal homeostasis human inflammation metabolism physiology Animals Galectin 1 Homeostasis Humans Inflammation T-Lymphocytes, Regulatory Vascular Endothelial Growth Factor A Galectin-1 as an Emerging Mediator of Cardiovascular Inflammation: Mechanisms and Therapeutic Opportunities |
| topic_facet |
ecalectin galectin galectin 1 galectin 12 glycan unclassified drug vasculotropin receptor galectin 1 vasculotropin A acute heart infarction antiinflammatory activity atherosclerosis brain ischemia cell differentiation cell expansion cell survival Chagas cardiomyopathy cytokine production heart failure immunocompetent cell mediator pulmonary hypertension regulatory T lymphocyte Review animal homeostasis human inflammation metabolism physiology Animals Galectin 1 Homeostasis Humans Inflammation T-Lymphocytes, Regulatory Vascular Endothelial Growth Factor A |
| description |
Galectin-1 (Gal-1), an evolutionarily conserved β-galactoside-binding lectin, controls immune cell homeostasis and tempers acute and chronic inflammation by blunting proinflammatory cytokine synthesis, engaging T-cell apoptotic programs, promoting expansion of T regulatory (Treg) cells, and deactivating antigen-presenting cells. In addition, this lectin promotes angiogenesis by co-opting the vascular endothelial growth factor receptor (VEGFR) 2 signaling pathway. Since a coordinated network of immunomodulatory and proangiogenic mediators controls cardiac homeostasis, this lectin has been proposed to play a key hierarchical role in cardiac pathophysiology via glycan-dependent regulation of inflammatory responses. Here, we discuss the emerging roles of Gal-1 in cardiovascular diseases including acute myocardial infarction, heart failure, Chagas cardiomyopathy, pulmonary hypertension, and ischemic stroke, highlighting underlying anti-inflammatory mechanisms and therapeutic opportunities. Whereas Gal-1 administration emerges as a potential novel treatment option in acute myocardial infarction and ischemic stroke, Gal-1 blockade may contribute to attenuate pulmonary arterial hypertension. © 2018 Ignacio M. Seropian et al. |
| title |
Galectin-1 as an Emerging Mediator of Cardiovascular Inflammation: Mechanisms and Therapeutic Opportunities |
| title_short |
Galectin-1 as an Emerging Mediator of Cardiovascular Inflammation: Mechanisms and Therapeutic Opportunities |
| title_full |
Galectin-1 as an Emerging Mediator of Cardiovascular Inflammation: Mechanisms and Therapeutic Opportunities |
| title_fullStr |
Galectin-1 as an Emerging Mediator of Cardiovascular Inflammation: Mechanisms and Therapeutic Opportunities |
| title_full_unstemmed |
Galectin-1 as an Emerging Mediator of Cardiovascular Inflammation: Mechanisms and Therapeutic Opportunities |
| title_sort |
galectin-1 as an emerging mediator of cardiovascular inflammation: mechanisms and therapeutic opportunities |
| publishDate |
2018 |
| url |
https://bibliotecadigital.exactas.uba.ar/collection/paper/document/paper_09629351_v2018_n_p_Seropian http://hdl.handle.net/20.500.12110/paper_09629351_v2018_n_p_Seropian |
| _version_ |
1768541997479493632 |